- Home
- ACB vs HUMA Comparison
ACB vs HUMA Comparison
Compare ACB & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | HUMA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 236.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACB | HUMA |
|---|---|---|
| Price | $4.54 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.13 |
| AVG Volume (30 Days) | 938.7K | ★ 4.8M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $263,570,704.00 | $1,571,000.00 |
| Revenue This Year | $9.42 | N/A |
| Revenue Next Year | $5.72 | $1,468.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.89 | N/A |
| 52 Week Low | $3.42 | $1.09 |
| 52 Week High | $6.91 | $6.77 |
Technical Indicators
Market Signals| Indicator | ACB | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 44.48 |
| Support Level | $4.45 | $1.09 |
| Resistance Level | $4.72 | $1.38 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 77.23 | 67.24 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.